Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) EBITDA (2016 - 2025)

Purple Biotech has reported EBITDA over the past 6 years, most recently at -$9.4 million for Q4 2022.

  • Quarterly EBITDA fell 294.81% to -$9.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2022, down 62.55% year-over-year, with the annual reading at $27.7 million for FY2025, 147.17% up from the prior year.
  • EBITDA was -$9.4 million for Q4 2022 at Purple Biotech, down from $5.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $8.4 million in Q4 2020 and troughed at -$9.4 million in Q4 2022.
  • The 5-year median for EBITDA is $3.7 million (2021), against an average of $3.7 million.
  • Year-over-year, EBITDA soared 128.86% in 2020 and then crashed 294.81% in 2022.
  • A 5-year view of EBITDA shows it stood at $3.5 million in 2018, then grew by 6.27% to $3.7 million in 2019, then soared by 128.86% to $8.4 million in 2020, then plummeted by 42.96% to $4.8 million in 2021, then crashed by 294.81% to -$9.4 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's EBITDA are -$9.4 million (Q4 2022), $5.1 million (Q3 2022), and $3.6 million (Q2 2022).